MyOli® LNT (Lacto-N-tetraose)

Disclaimer: Packaging in images is for visual representation only and may not reflect actual product packaging.

The human milk oligosaccharide LNT (Lacto-N-Tetraose) is one of the most abundant HMOs in breast milk and represents the group of basic neutral HMOs.

Get in touch

Product features, details and benefits

Details

MyOli is a trademark of Chr. Hansen A/S, part of Novonesis Group.

Safe handling

This product contains microbials. While microbial products are safe to use in consumer applications, they must be handled correctly in production environments to ensure that workers do not inhale organic dust and bioaerosols.

Please follow the precautionary handling recommendations below:

Avoid breathing dust/fume/gas/mist/vapors/spray
Avoid contact with eyes, skin, or clothing
In case of inadequate ventilation wear respiratory protection
IF INHALED: Remove person to fresh air and keep comfortable for breathing
Store in a dry place. Store in a closed container
Dispose of contents/containers in accordance with local regulations

For recommendations on how to safely handle the microbial product, please visit the guide.

Get in touch

Fill out the form below and one of our experts will contact you shortly.

One more step…

To complete the get in touch form or sign up, please click on the button below to enable cookies.

^{1 Bode, Lars. “Human milk oligosaccharides: prebiotics and beyond.” Nutrition reviews 67.suppl_2 (2009): S183-S191.}
^{2 Gotoh, Aina, et al. “Sharing of human milk oligosaccharides degradants within bifidobacterial communities in faecal cultures supplemented with Bifidobacterium bifidum.” Scientific reports 8.1 (2018): 1-14.}
^{3 Özcan, Ezgi, and David A. Sela. “Inefficient metabolism of the human milk oligosaccharides lacto-N-tetraose and lacto-N-neotetraose shifts Bifidobacterium longum subsp. infantis physiology.” Frontiers in Nutrition 5 (2018): 46.}
^{4 Craft, Kelly M., and Steven D. Townsend. “The human milk glycome as a defense against infectious diseases: rationale, challenges, and opportunities.” ACS infectious diseases 4.2 (2018): 77-83.}
^{5 El-Hawiet, Amr, Elena N. Kitova, and John S. Klassen. “Recognition of human milk oligosaccharides by bacterial exotoxins.” Glycobiology 25.8 (2015): 845-854.}
^{6 Lin, Ann E., et al. “Human milk oligosaccharides inhibit growth of group B Streptococcus.” Journal of Biological Chemistry 292.27 (2017): 11243-11249.}

Disclaimer

This content is intended exclusively for business-to-business purposes for a professional audience only and is not intended to target consumers.